Literature DB >> 10946899

All-trans-retinoic acid modulates expression levels of thyroglobulin and cytokines in a new human poorly differentiated papillary thyroid carcinoma cell line, KTC-1.

J Kurebayashi1, K Tanaka, T Otsuki, T Moriya, H Kunisue, M Uno, H Sonoo.   

Abstract

A new human thyroid carcinoma cell line, KTC-1, was established from the malignant pleural effusion of a recurrent thyroid carcinoma patient. Cytogenetic analysis revealed a normal karyotype, and no p53 mutation in exons 5-9 was detected. This cell line is tumorigenic in athymic nude mice. Histological findings by light and electron microscopy, such as the absence of follicular structures and the existence of intranuclear cytoplasmic inclusions and psammoma bodies, indicated transplanted tumors to be a poorly differentiated papillary thyroid carcinoma. A low expression level of thyroglobulin was detected by immunocytochemistry and RT-PCR. Messenger ribonucleic acid (mRNA) expression of thyroid transcription factor-1 and PAX-8 was also detected. No mRNA expression of TSH receptors, thyroid peroxidase, or Na+/I- symporter was detected. Interleukin-6 and leukemia inhibitory factor were secreted into the medium. These findings suggest this cell line to be functionally poorly differentiated. Moreover, all-trans-retinoic acid increased the mRNA expression of thyroglobulin and decreased both the mRNA expression and secretion of interleukin-6 and leukemia inhibitory factor while significantly stimulating growth. RT-PCR analysis of retinoic acid receptors (RARs) revealed that KTC-1 cells express a moderate level of RARalpha and -gamma, but a low level of RARbeta. This cell line may be useful for studying redifferentiation therapy for thyroid carcinoma.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10946899     DOI: 10.1210/jcem.85.8.6732

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  35 in total

Review 1.  The role of apoptosis in autoimmune thyroid disorders and thyroid cancer.

Authors:  J D Lin
Journal:  BMJ       Date:  2001-06-23

2.  Involvement of centrosomes in nuclear irregularity of thyroid carcinoma cells.

Authors:  Dongfeng Niu; Shin-ichi Murata; Tetsuo Kondo; Tadao Nakazawa; Tomonori Kawasaki; Defu Ma; Tetsu Yamane; Nobuki Nakamura; Ryohei Katoh
Journal:  Virchows Arch       Date:  2009-07-09       Impact factor: 4.064

3.  Histone deacetylase inhibitors upregulate Rap1GAP and inhibit Rap activity in thyroid tumor cells.

Authors:  Xiaoyun Dong; Christopher Korch; Judy L Meinkoth
Journal:  Endocr Relat Cancer       Date:  2011-04-02       Impact factor: 5.678

4.  Prospective evaluation of (68)Ga-DOTANOC PET-CT in differentiated thyroid cancer patients with raised thyroglobulin and negative (131)I-whole body scan: comparison with (18)F-FDG PET-CT.

Authors:  Parveen Kundu; Sneh Lata; Punit Sharma; Harmandeep Singh; Arun Malhotra; Chandrasekhar Bal
Journal:  Eur J Nucl Med Mol Imaging       Date:  2014-02-22       Impact factor: 9.236

5.  Functional analysis of three novel cell lines derived from human papillary thyroid carcinomas with three different clinical courses.

Authors:  Mayumi Ishikawa; Toshiaki Tachibana; Hisashi Hashimoto; Junko Toyomura; Toshihide Ito; Kumiko Tsuboi; Kazutoshi Shibuya; Takahisa Hirose; Shiro Minami; Gen Yoshino
Journal:  Hum Cell       Date:  2014-02-25       Impact factor: 4.174

6.  Group I p21-activated kinases regulate thyroid cancer cell migration and are overexpressed and activated in thyroid cancer invasion.

Authors:  Samantha K McCarty; Motoyasu Saji; Xiaoli Zhang; David Jarjoura; Alfredo Fusco; Vasyl V Vasko; Matthew D Ringel
Journal:  Endocr Relat Cancer       Date:  2010-10-29       Impact factor: 5.678

Review 7.  Potential utility and limitations of thyroid cancer cell lines as models for studying thyroid cancer.

Authors:  Tania Pilli; Kanteti V Prasad; Shankar Jayarama; Furio Pacini; Bellur S Prabhakar
Journal:  Thyroid       Date:  2009-12       Impact factor: 6.568

8.  Pericytes Elicit Resistance to Vemurafenib and Sorafenib Therapy in Thyroid Carcinoma via the TSP-1/TGFβ1 Axis.

Authors:  Alessandro Prete; Agnes S Lo; Peter M Sadow; Swati S Bhasin; Zeus A Antonello; Danica M Vodopivec; Soumya Ullas; Jennifer N Sims; John Clohessy; Ann M Dvorak; Tracey Sciuto; Manoj Bhasin; Joanne E Murphy-Ullrich; Jack Lawler; S Ananth Karumanchi; Carmelo Nucera
Journal:  Clin Cancer Res       Date:  2018-08-03       Impact factor: 12.531

9.  Growth inhibition of thyroid follicular cell-derived cancers by the opioid growth factor (OGF) - opioid growth factor receptor (OGFr) axis.

Authors:  Patricia J McLaughlin; Ian S Zagon; Sunny S Park; Andrea Conway; Renee N Donahue; David Goldenberg
Journal:  BMC Cancer       Date:  2009-10-18       Impact factor: 4.430

10.  13-cis-retinoic acid re-differentiation therapy and recombinant human thyrotropin-aided radioiodine treatment of non-Functional metastatic thyroid cancer: a single-center, 53-patient phase 2 study.

Authors:  Daria Handkiewicz-Junak; Jozef Roskosz; Kornelia Hasse-Lazar; Sylwia Szpak-Ulczok; Zbigniew Puch; Aleksandra Kukulska; Tomasz Olczyk; Andrzej Piela; Ewa Paliczka-Cieslik; Barbara Jarzab
Journal:  Thyroid Res       Date:  2009-08-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.